EUCTR2013-004768-72-DE进行中（未招募）1 期
A randomized, double-blind, parallel-group, multicenter Phase 2b study to assess the efficacy and safety of two different doses of vilaprisan (BAY 1002670) versus placebo in women with symptomatic endometriosis - villendo
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Bayer AG
- 入组人数
- 315
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Signed and dated informed consent
- •2. Pre-menopausal women 18 years (inclusive) and above at the time of Visit 1
- •3. Women with endometriosis confirmed by laparoscopy or laparotomy OR diagnosed based on imaging
- •4. Moderate to severe endometriosis-associated pelvic pain (EAPP)
- •5. Adherence to screening period diary entries
- •6. Willingness to use only standardized pain medication if needed
- •7. Good general health (except for findings related to endometriosis)
- •8. Normal or clinically insignificant cervical cytology not requiring further follow-up
- •9. An endometrial biopsy performed at the screening phase without significant histological disorder
- •10. Use of an acceptable non-hormonal method of contraception
- •11. Willingness / ability to comply with electronic diary entry for the duration of study participation
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 315
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Pregnancy or lactation (less than 3 months since delivery, abortion, or lactation before Visit 1)
- •2. Hypersensitivity to any ingredient of the study treatments
- •3. Laboratory values outside the inclusion range before randomization, and considered clinically relevant
- •4. Any diseases or conditions that can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study drug including abnormal liver parameters
- •5. Any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results
- •6. Undiagnosed abnormal genital bleeding
- •7. Abuse of alcohol, drugs, or medicines (e.g. laxatives) as evaluated by the investigator
- •8. Use of other treatments that might interfere with the conduct of the study or the interpretation of the results
- •9. Endometriosis-specific treatments for symptom relief except rescue pain medication according to protocol
- •10. Simultaneous participation in another clinical trial with investigational medicinal product(s). Participation in another trial prior to study entry that might have an impact on the study objectives, at the discretion of the investigator
- •11. Inability to cooperate with the study procedures for any reason
- •12. Previous assignment to treatment (e.g. randomization) during this study (allowing previously randomized subjects to be re-included into the study may lead to bias)
- •13. Hypersensitivity to any ingredient of standardized pain medication
- •14. Wish for pregnancy during the study
- •15. Regular use of pain medication due to other underlying diseases
- •16. Non-responsiveness of EAPP to GnRH-a
研究者
相似试验
进行中（未招募）
1 期
Study of safety, tolerability and efficacy of a combination treatment of tropifexor (LJN452) & licogliflozin (LIK066) in adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosisEUCTR2019-002324-32-ITOVARTIS PHARMA AG233
进行中（未招募）
1 期
Study of safety, tolerability and efficacy of a combination treatment of tropifexor (LJN452) & licogliflozin (LIK066) and each monotherapy, compared with placebo in adult participants with nonalcoholic steatohepatitis (NASH) and liver fibrosisEUCTR2019-002324-32-SKovartis Pharma AG380
招募中
2 期
Clinical trial to compare the efficacy and tolerability of fulvestrant (FaslodexTM) 500mg with placebo versus fulvestrant (FaslodexTM) 500mg with PD-0332991 (Palbociclib), randomly assigned, as first line treatment for postmenopausal women with hormone receptor-positive metastatic breast cancer, who have completed at least 5 years of hormonal therapy and remained disease free for more than 12 months following its completion or who have metastatic disease diagnosed from the beginning.Metastatic breast cancer2024-516132-10-00Fundacion Grupo Espanol De Investigacion En Cancer De Mama189
进行中（未招募）
1 期
Assess safety and efficacy of vilaprisan in subjects with endometriosisEUCTR2013-004768-72-ESBayer AG315
进行中（未招募）
不适用
A randomized, double-blind, parallel-group, multicenter study to demonstrate improvement in symptoms of constipation in subjects with non-malignant pain taking oxycodone equivalent of >= 20 mg/day and <= 50 mg/day as oxycodone / naloxone prolonged release compared to subjects taking oxycodone prolonged release tablets alone.Moderate to severe non-malignant pain that requires around the clock opioid therapy and also have constipation secondary to opioid treatment.MedDRA version: 8.1Level: LLTClassification code 10049475Term: Chronic painEUCTR2005-002398-57-CZMundipharma Research GmbH & Co. KG600